

Leukaemia & Lymphoma NI

Report and Financial Statements

Year ended 31 July 2017

Leukaemia & Lymphoma NI

<i>Contents</i>	<i>Page</i>
Legal and administrative information	1
Trustees' report	2
Statement of trustees' responsibilities	7
Independent auditors' report	8
Statement of financial activities	10
Statement of financial position	12
Statement of cash flows	13
Notes on and forming part of the financial statements	14

Leukaemia & Lymphoma NI

Legal and administrative information

Trustees	Trustee Trustee Trustee Trustee Trustee	Mr Richard Buchanan (Chairperson) Mr Bill Pollock Mrs Barbara McClatchey Mrs Shirley Sinclair Mr David Montgomery
Non-trustee office bearers	Patron Secretary Treasurer Public Relations Officer	Professor Jim Dornan Mrs Hazel Black Ms Heather McComb Mrs Frances Parker
Auditors	Hill Vellacott Chartered Accountants Chamber of Commerce House 22 Great Victoria Street Belfast	
Bankers	Ulster Bank Limited City Branch Donegall Square East Belfast	
Solicitors	Edwards & Co 28 Hill Street Belfast	
Principal office	Centre for Cancer Research and Cell Biology Belfast City Hospital 97 Lisburn Road Belfast	
HMRC reference	XN048014	

Leukaemia & Lymphoma NI

Trustees' report

The trustees have pleasure in submitting their annual report together with the audited financial statements of LLNI for the year ended 31 July 2017.

The trustees have adopted the provisions of the Charities SORP (FRS 102) in preparing their annual report and financial statements of the charity.

Legal and administrative information on page 1 forms part of this report.

Objectives and activities

Leukaemia & Lymphoma NI is an unincorporated Members Association governed by its Constitution, amended and updated 19 June 2013. Its objects are to promote research into the causes and cure of leukaemia, lymphoma and other associated blood cancers in Northern Ireland.

History of LLNI

Leukaemia & Lymphoma NI (previously Northern Ireland Leukaemia Research Fund) was established in 1964 by the parents of a teenage girl who died of leukaemia. It is supported throughout the province especially by relatives and friends of patients affected by these diseases. Over the last 50 years they have established a number of branches and raised approximately £9million.

Leukaemia & Lymphoma NI (LLNI) invites applications from scientists and doctors for grants to investigate some particular aspects of the diseases. LLNI has awarded grants to universities, particularly to Queen's University, Belfast, to establish a Chair of Haematology, to carry out fundamental research on the mechanisms involved in blood formation and the development of leukaemia, lymphoma and other associated blood cancers.

All grant applications to LLNI are reviewed by a Medical Advisory Committee, chaired by a former professor of haematology, supported by local experts and colleagues from London and Dublin. Grant applications are subjected to rigorous scrutiny in accordance with the guidelines laid down by the Association of Medical Research Charities of which LLNI is a member.

In April 2007 the group moved to the Centre for Cancer Research and Cell Biology at Belfast City Hospital, remaining part of the Cancer Research Centre which obtained a Grade 5 in the 2001 University Research Assessment Exercise, denoting work of international repute.

LLNI also maintains links with Leukaemia & Lymphoma Research with which it co-operates in pursuit of its charitable objectives.

It is of great importance to LLNI to determine if the incidence and type of blood cancers is changing throughout the province and to this end a Register of Leukaemia and Lymphoma has been established in collaboration with similar registers throughout the UK. Support from LLNI has enabled the highest standard of care to be available for patients and allow Northern Ireland researchers to make significant contributions to the understanding of the nature of these diseases.

Leukaemia & Lymphoma NI

Trustees' report

Review of activities and future developments

Leukaemia & Lymphoma NI had 3 branches in the province during the year as follows:

- Bangor and district
- Belfast
- East Antrim

Each branch is self-contained and conducts its own fund raising activities. These vary from branch to branch, but include such activities as street collections, Christmas card sales, fairs, concerts, fashion shows, sales of work, golf tournaments, sponsored runs and a host of other activities too numerous to mention.

At the Annual General Meeting each branch outlines its' fund raising events and indicates the amount of money raised. Funds are also generated through donations, many in the memory of someone who has died from leukaemia or from the family of those where a cure has been affected. Other sources are interested individuals and organisations.

Legacies are another important source of revenue (see page 16). A Medical Advisory Committee is responsible for recommending to LLNI's Central Committee suitable research programmes.

Leukaemia & Lymphoma NI

Based upon the advice of the Medical Advisory Committee of LLNI financial support is provided to the Haematology Research Group (HRG) at Queen's University Belfast. LLNI actually supports the laboratory work of four Principal Investigators who lead small groups of researchers working on various haematological diseases.

Professor Ken Mills

Professor Ken Mills is Chair of Experimental Haematology within the blood cancer research group. His research is focused on Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS) using high density micro arrays, miRNA and epigenetic profiling. These assays involve the simultaneous analysis of large numbers of RNA or miRNAs targets with the aim of disease classification, improving prognostic markers and identifying and screening novel therapies.

Professor Mills is Chair of the EU COST Action entitled "European Genomic and Epigenetic Study on MDS and AML", a consortium of laboratories in 22 EU countries. He is also Lead for the Belfast Experimental Cancer Medicine Centre (ECMC), Head of the Experimental Cancer Medicine Research Division in the CCRCB and Academic Lead for the Core Technology Units in the School of Medicine. Professor Mills is a member of the Executive Committees of the Northern Ireland Cancer Registry and Northern Ireland Cancer Trials Centre. Professor Mills sits on the Scientific Review Committee of the Northern Ireland BioBank and the Northern Ireland Cohort Study for the Longitudinal Study of Ageing (NICOLA). He is a regional committee member of the Royal College of Pathologists and an Examiner for the Clinical Scientist programme.

Leukaemia & Lymphoma NI have awarded Professor Mills an infrastructure grant which has been used to fund travel to research workshops, conferences and meetings, small items of equipment and contributes to consumables for all projects within the HRG.

Leukaemia & Lymphoma NI

Trustees' report

Professor Mary Frances McMullin

Professor Mary Frances McMullin is Professor of Clinical Haematology in Queens University Belfast and Consultant Haematologist to Belfast Health and Social Care Trust. Her research focuses on erythrocytosis, myeloproliferative neoplasms and acute myeloid leukaemia looking at the causes of erythrocytosis and the pathogenesis, epidemiology and treatment modalities in the neoplastic disorders. She has an extensive portfolio of clinical trials in the clinical areas of interest.

Professor McMullin is involved on the management committee of the network of experts in the molecular diagnosis of myeloproliferative neoplasms and related disease MPN&MPN-EuroNET COST Action BM0902 and is chair of Working Group 3 in this COST action. Professor McMullin was President of the Haematology Association of Ireland (2010-2011). Professor McMullin was Chair of the MPN Sub Group from 2006 – 2011 and Chair of the British Committee for Standards in Haematology 2011 – 2015.

She is a long-term member of the executive committee of the Northern Ireland Cancer Clinical Trials centre and the Belfast Experimental Cancer medicine Centre, and an examiner for the Royal College of Pathologists and the Royal College of Physicians of Edinburgh. She is a Fellow of the Academy of Medical Educators and has extensive commitments in Education in Haematology including for the European Haematology Association and this year the Mumbai Haematology Group.

Core Tissue Support

LLNI provides core tissue culture support through an annual grant for laboratory infrastructure support for experiments involving cellular and molecular biological techniques.

Ph.D Studentships

LLNI currently funded a four year PhD studentship. The studentship was awarded in 2010 to Gemma Logan, who carried out research into the role of ankyrin repeat and SOCS box proteins (ASBs) in AML (jointly supervised by Professor Ken Mills and Dr Melanie Percy). In addition, in early 2013, an opportunity arose for LLNI to jointly support a PhD studentship with DEL. As a result Christine Young, supervised by Prof Mills and Dr Thompson, started her studies in February 2013.

Golden Anniversary Research Programme

In 2015 LLNI announced a £500,000 investment to coincide with their 50th Anniversary. This investment is to support research into leukaemia, lymphoma, myeloma and other related disorders; through 2 PhD programmes, 2 Post Doctoral Fellowships and 1 Clinical Fellow.

Summer Studentships

LLNI have supported five eight-week summer studentships in the Centre for Cancer Research and Cell Biology (CCRCB), Queen's University Belfast. Studentships provide an opportunity for undergraduate students with an interest in research to gain experience of working in the laboratories on a leukaemia-related project. The students contribute to a number of projects being undertaken by the Haematology Research Group.

Leukaemia & Lymphoma NI

Trustees' report

Financial review

Details of the results for the year are set out in the statement of financial activities on pages 10 and 11 and the related notes.

Investment policy and returns

LLNI's investments are managed by Cunningham Coates Stockbrokers Belfast and were valued at £1,500,632 as at 31 July 2017.

During the past financial year we have received dividend income from these investments totalling £88,697 which is most satisfactory.

The Central Committee of LLNI are very pleased with the relationship formed with Cunningham Coates Stockbrokers and their expertise in dealing with our investments.

Reserves

The Trustees have reviewed the resources of LLNI taking into consideration the variable natures of its income and the need to fulfil the fixed commitment of grant to Queen's University as formalised and confirmed to the University for the period 1 October to 30 September in each year.

Governance and internal control

The organisation structure of LLNI is as set out in the Constitution of LLNI at paragraph 10:

"The following officers, all of whom shall be honorary, that is to say, a Patron, a President, a Chairperson, one or more Vice Chairpersons, a Secretary, a Treasurer and a Public Relations Officer shall be elected annually in such a manner and shall discharge such duties as LLNI in general meeting shall from time to time determine".

The major risks to which LLNI would be exposed are centred around the following areas:

i Misuse and misappropriation of funds coupled with poor financial controls.

LLNI's objective is to raise money to finance appropriate research into the causes and possible cures for leukaemia, lymphoma and other associated blood cancers. This research is controlled, supervised and vetted by LLNI's Medical Advisory Committee (MAC) under the Chairmanship of Professor TCM Morris, assisted by a group of eminent academics. Research projects are carefully scrutinised and "peer reviewed" by the MAC before any recommendations are made within the budgetary confines of LLNI.

The funds to support research are carefully controlled by the Central Committee of LLNI, which received a financial report by the honorary treasurer at each meeting of the Central Committee which meets several times a year under the Chairmanship of Mr Richard Buchanan. A Financial Sub-Committee under the Chairperson to LLNI oversees the finances of LLNI and also reports to the Central Committee.

Leukaemia & Lymphoma NI

Trustees' report

ii Lack of proper public liability insurance to cover fund raising activities by members and the possibility of legal action against members.

Members' fund raising activities are covered for public liability by LLNI's insurance brokers. Members have been circularised that any activity which has the slightest element of risk must have the approval of the insurers before proceeding. High risk activities are not permitted.

Auditors

Hill Vellacott have expressed their willingness to continue in office as auditors and a resolution for their re-appointment will be proposed at the Annual General Meeting.

By order of the board on 15 November 2017

Mr Richard Buchanan
Chairman

Leukaemia & Lymphoma NI

Statements of trustees' responsibilities

The constitution of Leukaemia & Lymphoma NI requires the trustees to prepare financial statements for each financial period which give a true and fair view of the state of affairs of LLNI and of the surplus or deficit of LLNI for that period. In preparing those financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that LLNI will continue in business.

The trustees are responsible for maintaining proper accounting records which disclose with reasonable accuracy at any time the financial position of LLNI and to enable them to ensure that the financial statements comply with the Charities Act (Northern Ireland) 1964 and the Charities (Northern Ireland) Order 1987. They have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of LLNI and to prevent and detect fraud and other irregularities.

The trustees of the Charity who held office at the date of approval of these financial statements, as set out on page 1, each confirm so far as we are aware that:

- there is no relevant audit information of which the Charity's auditors are unaware; and
- we have taken all the steps that we ought to have taken as trustees in order to make ourselves aware of any relevant audit information and to establish that the Charity's auditors are aware of that information.

By order of the board on 15 November 2017

Mr Richard Buchanan
Chairman

Independent auditors' report to the members of Leukaemia & Lymphoma NI

We have audited the financial statements of Leukaemia & Lymphoma NI for the year ended 31 July 2017 which comprise statement of Statement of Financial Activities, Statement of Financial Position, the Statement of Cash Flows and the related notes. These financial statements have been prepared under the historical cost convention and the accounting policies set out therein.

This report is made solely to LLNI's trustees, as a body, in accordance with the Charities Act (Northern Ireland) 1964 and the Charities (Northern Ireland) Order 1987. Our audit work has been undertaken so that we might state to LLNI's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than LLNI and LLNI's members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of trustees and auditors

As described in the Statement of Trustees' Responsibilities LLNI's trustees are responsible for the preparation of financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom General Accepted Accounting Practice).

Our responsibility is to audit the financial statements in accordance with relevant legal and regulatory requirements and International Standards on Auditing (UK and Ireland).

We report to you our opinion as to whether the financial statements give a true and fair view and are properly prepared in accordance with the Charities Act (Northern Ireland) 1964 and the Charities (Northern Ireland) Order 1987. We also report to you if, in our opinion, the Trustees' Report is not consistent with the financial statements, if LLNI has not kept proper accounting records, if we have not received all the information and explanations we require for our audit, or if information specified by law regarding trustees' remuneration and transactions with LLNI is not disclosed.

We read the Trustees' Report and consider the implications for our report if we become aware of any apparent misstatement within it.

Basis of audit opinion

We conducted our audit in accordance with International Standards on Auditing (UK and Ireland) issued by the Auditing Practices Board. An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the financial statements. It also includes an assessment of the significant estimates and judgements made by the trustees in the preparation of the financial statements, and of whether the accounting policies are appropriate to LLNI's circumstances, consistently applied and adequately disclosed.

Independent auditors' report to the members of Leukaemia & Lymphoma NI

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion we also evaluated the overall adequacy of the presentation of information in the financial statements.

Opinion

In our opinion, the financial statements give a true and fair view, in accordance with United Kingdom Generally Accepted Accounting Practice, of the state of LLNI's affairs as at 31 July 2017 and of the incoming resources and application of resources for the year then ended. The financial statements have been properly prepared in accordance with the Charities Act (Northern Ireland) 1964 and the Charities (Northern Ireland) Order 1987.

In our opinion the information given in the Trustees' Report is consistent with the financial statements.

Mr Patrick Hegarty, FCCA (Senior Statutory Auditor)

For and on behalf of Hill Vellacott, Statutory Auditor

Chartered Accountants

Leukaemia & Lymphoma NI

Statement of Financial Activities (including Income and Expenditure Account) Year ended 31 July 2017

		Unrestricted funds	Restricted funds	2017 Total	2016 Total
	Note	£	£	£	£
Income and Endowments					
Income from charitable activities					
Donations and gifts	2	494,688		494,688	339,345
Legacies	3	50,936		50,936	3,687
Activities for generating funds	4	40		40	372
Stem cell harvest		13,920		13,920	10,920
Investment income	5	89,034		89,034	84,479
Sundry Income		-		-	-
Profit/(loss) on disposal of investments		59,412		59,412	7,638
		<hr/>	<hr/>	<hr/>	<hr/>
Total incoming resources		708,030		708,030	446,441
		<hr/>	<hr/>	<hr/>	<hr/>
Resources expended					
Cost of generating funds					
Fundraising trading: Cost of goods sold and other costs		2,260		2,260	1,839
Charitable expenditure					
Grants towards:					
– salaries		575,127		575,127	342,407
– supplies and equipment		152,218		152,218	110,591
– travelling expenses		16,542		16,542	7,856
Charitable activities	7	61,957		61,957	53,964
		<hr/>	<hr/>	<hr/>	<hr/>
Total resources expended		808,104		808,104	516,657
		<hr/>	<hr/>	<hr/>	<hr/>
Net resources expended		(100,074)		(100,074)	(70,216)
Movement on valuation of investments		71,112		71,112	(27,078)
		<hr/>	<hr/>	<hr/>	<hr/>
Net movement in funds		(28,962)		(28,962)	(97,294)
Fund balances brought forward		1,801,140		1,801,140	1,898,434
		<hr/>	<hr/>	<hr/>	<hr/>
Fund balance carried forward		1,772,178		1,772,178	1,801,140
		<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

Leukaemia & Lymphoma NI

Statement of Financial Activities *(including Income and Expenditure Account)* *Year ended 31 July 2017*

LLNI has no recognised gains or losses other than those included on the preceding page and therefore no separate statement of total recognised gains and losses has been presented.

The incoming resources and resources expended amounts as stated on the preceding page are derived solely from continuing operations.

The notes on pages 14 to 19 form part of these financial statements.

Leukaemia & Lymphoma NI

Statement of Financial Position

31 July 2017

	<i>Note</i>	2017		2016	
		£	£	£	£
Fixed assets					
Intangible fixed assets			790		790
Investments at market value	9		1,500,632		1,740,662
Current assets					
Stock		1,000		1,000	
Prepayments		1,089		1,147	
Cash at bank	10	362,206		199,483	
			<u>364,295</u>		<u>201,630</u>
Current liabilities					
Accruals		(93,539)		(141,942)	
			<u>270,756</u>		<u>59,688</u>
Net current assets					
			<u>1,772,178</u>		<u>1,801,140</u>
Funds					
Unrestricted funds - general funds	12		735,516		989,333
- designated funds			1,036,662		811,807
Restricted funds			-		-
			<u>1,772,178</u>		<u>1,801,140</u>

The financial statements were approved by the Trustees on 15 November 2017 and signed on its behalf by:

Mr Richard Buchanan
Chairman

The notes on pages 14 to 19 form part of these financial statements.

Leukaemia & Lymphoma NI

Statement of Cash Flows

31 July 2017

	2017	2016
	£	£
Cash flows from charitable activities		
(loss) / surplus for the financial year	(28,962)	(97,294)
<i>Adjustments for:</i>		
Interest received	(337)	(936)
Movement on valuation of investments	(71,112)	27,078
Gain on disposal of investments	(59,412)	(7,638)
Accrued expenses	(48,403)	(20,827)
<i>Changes in:</i>		
Stock	-	-
Prepayments	58	(257)
	<hr/>	<hr/>
Cash generated from charitable activities	(208,168)	(99,874)
Interest received	337	936
	<hr/>	<hr/>
Net cash from charitable activities	(207,831)	(98,938)
	<hr/> <hr/>	<hr/> <hr/>
Cash flows from investing activities		
Purchase of shares	(302,208)	(272,709)
Proceeds from sale of shares	627,571	135,911
	<hr/>	<hr/>
Net cash used in investing activities	325,363	(136,798)
	<hr/> <hr/>	<hr/> <hr/>
Net increase/(decrease) in cash and cash equivalents	117,532	(235,736)
Cash and cash equivalents at beginning of year	277,790	513,526
	<hr/>	<hr/>
Cash and cash equivalents at end of year	395,322	277,790
	<hr/> <hr/>	<hr/> <hr/>
Cash and cash equivalents		
Cash at bank	362,206	199,483
Investment cash accounts	33,116	78,307
	<hr/>	<hr/>
	395,322	277,790
	<hr/> <hr/>	<hr/> <hr/>

Leukaemia & Lymphoma NI

Notes

forming part of the statement of accounts

1 Accounting policies

The accounting policies are consistent with those of the previous year.

(i) Basis of accounting

LLNI prepares its financial statements under historical cost convention, as modified by the inclusion of investments at market value. The financial statements have been prepared in accordance with the Charities SORP (FRS 102).

(ii) Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the charity and have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by LLNI for particular purposes. The cost of raising and administering such funds are charged against the specific fund.

Designated funds are unrestricted funds that have been set aside by the trustees for particular purposes. Details of the designated funds are described in note 12.

Investment income and gains are allocated to the unrestricted fund.

(iii) Incoming resources

All incoming resources are included in the statement of financial activities when the charity is legally entitled to the income and the amount can be quantified with reasonable accuracy. For legacies, entitlement is the earlier of the charity being notified of an impending distribution or the legacy being received.

Gifts in kind donated for distribution are included at valuation and recognised as income when they are distributed to the projects. Gifts donated for resale are included as income when they are sold. Donated facilities are included at the value to the charity where this can be quantified and a third party is bearing the cost. No amounts are included in the financial statements for services donated by volunteers.

Due to the nature of donated income, such income is not capable of control by LLNI and branches before receipt. However, financial controls are in place to ensure accurate recording and safeguarding of all income received by LLNI.

Leukaemia & Lymphoma NI

Notes

forming part of the statement of accounts

1 Accounting policies (continued)

(iv) Resources expended

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

Grants payable for research are included in the statement of financial activities when approved by the trustees after review by a medical advisory committee. The value of grants unpaid at the year end is accrued.

Management and administration costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

(v) Investments

Investments are stated at market value at the balance sheet date. The statement of financial activities includes the net gains and losses arising on revaluations and disposals throughout the year.

2 Donations and gifts

	Unrestricted £	Restricted £	2017 £	2016 £
Income from general donations	417,018		417,018	294,217
Gift Aid	7,713		7,713	-
Branches				
Bangor and district	12,000		12,000	11,506
East Antrim	48,000		48,000	25,624
Lisburn	9,725		9,725	1,810
Strabane	232		232	6,188
	<hr/>	<hr/>	<hr/>	<hr/>
	494,688		494,688	339,345
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

Leukaemia & Lymphoma NI

Notes

forming part of the statement of accounts

3 Legacies

	2017 £	2016 £
From the estate of:		
T. Walker	-	951
B. Currie	-	1,000
S. Foster	740	-
M. Rawson	5,000	-
J.C. Clayton	-	1,667
K. McAllister	5,000	-
W.A. Curry	-	69
W. Buchanan	3,996	-
T. Dickson McNaul	36,000	-
D.J. Caddoo	200	-
	<hr/>	<hr/>
	50,936	3,687
	<hr/> <hr/>	<hr/> <hr/>

All the legacies are unrestricted.

4 Sale of Goods

Promotional items such as pens, T-shirts, wedding favours, badges and wrist bands are sold on the website leukaemia&lymphomani.org.

5 Investment income

	2017 £	2016 £
Bank interest	333	904
Other interest	4	32
Dividends	88,697	83,543
	<hr/>	<hr/>
	89,034	84,479
	<hr/> <hr/>	<hr/> <hr/>

6 Staff numbers and costs

LLNI had no employees during the year. LLNI pays grants to Queen's University towards the salaries of employees working on leukaemia research.

Leukaemia & Lymphoma NI

Notes

forming part of the statement of accounts

7 Charitable activities

	2017 £	2016 £
Insurance	998	958
Stationery	-	1,047
Audit and accountancy	3,680	4,200
Legal	2,838	360
Events management	9,143	-
Sundry expenses	374	839
Promotion and advertising	34,302	35,223
Investment management charges	7,570	7,077
Bank fees	35	-
Telephone	443	411
Computer costs	1,371	2,817
Subscriptions	1,203	1,032
	<hr/>	<hr/>
	61,957	53,964
	<hr/> <hr/>	<hr/> <hr/>

8 Net outgoing resources

Net outgoing resources are stated after charging:

	2017 £	2016 £
Auditors' remuneration	3,540	3,600
	<hr/> <hr/>	<hr/> <hr/>

9 Fixed asset investments

	2017 £	2016 £
At 1 August 2016	1,662,355	1,544,997
Additions at cost	302,208	272,710
Disposal proceeds	(627,571)	(135,912)
Profit on disposal	59,412	7,638
Revaluation	71,112	(27,078)
	<hr/>	<hr/>
	1,467,516	1,662,355
Monies held	33,116	78,307
	<hr/>	<hr/>
At 31 July 2017	1,500,632	1,740,662
	<hr/> <hr/>	<hr/> <hr/>

Leukaemia & Lymphoma NI

Notes

forming part of the statement of accounts

10 Cash at bank

	2017 £	2016 £
Current account	264,760	92,208
Branch bank accounts	5,186	15,201
Special interest bearing account	92,238	92,074
Petty cash	22	-
	<hr/>	<hr/>
At 31 July 2017	362,206	199,483
	<hr/> <hr/>	<hr/> <hr/>

11 Branch Donations received and transfers to central account

Branch	Opening bank balance 01/08/16	Net Donations Lodged to Bank £	Expenses £	Amount transferred to central account £	Closing bank balance 31/07/17 £
Bangor	5,504	6,781	-	(12,000)	285
East Antrim	9,697	46,979	(3,775)	(48,000)	4,901
	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>
	15,201	53,760	(3,775)	(60,000)	5,186
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

Leukaemia & Lymphoma NI

Notes

forming part of the statement of accounts

12 Unrestricted funds

	Balance at 1 August 2016	Transfer to / (from) designated funds	Income	Expenses	Balance at 31 July 2017
	£		£	£	£
General reserves	989,333	(968,743)	714,926	-	735,516
Designated funds					
Stem Cell Harvest	17,920	30,558		(12,638)	35,840
General account for consumables	54,552	3,520		(28,072)	30,000
Core tissue culture support	44,208	(12,747)		(11,461)	20,000
Staff administered by the Belfast City Hospital Trust	84,500	(84,500)		-	-
Grade 4 clerical officer	25,091	46,433		(21,342)	50,182
Chair of experimental Haematology	117,500	72,082		(87,787)	101,795
NILRF Coordinator expenses	26,000	10,484		(33,484)	3,000
Travel Grant – Dr AE Irvine	1,000	(453)		(547)	-
Summer studentships	2,001	(2,001)		-	-
Consumables	5,000	(2,973)		(2,027)	-
Dr L Crawford Golden Anniversary Programmes:					
PhD Studentship	121,058	-		(23,401)	97,657
PhD Studentship	40,455	3,861		(36,816)	7,500
Post Doctoral Fellowship	103,477	(49,701)		(32,276)	21,500
Post Doctoral Fellowship	76,959	11,123		(51,082)	37,000
Clinical Research Fellowship	62,086	(1,685)		(53,901)	6,500
NI Patients in trials	30,000	-		-	30,000
Clinical trials nurse	-	18,600		(18,600)	-
PhD Studentship	-	17,257		(17,257)	-
PhD Studentship	-	97,133		-	97,133
Senior Lecturer and Clinical Research Fellow	-	790,555		(300,000)	490,555
Research Studentship	-	13,500		(5,500)	8,000
Others	-	7,697		(7,697)	-
	<u>1,801,140</u>	<u>-</u>	<u>714,926</u>	<u>743,888</u>	<u>1,772,178</u>

The general reserve fund represents those funds which are unrestricted and not designated for other purposes.

The designated funds have been set aside by LLNI for the department of Haematology, CCRCP, Belfast City Hospital mainly to aid with the administration of research projects.